Prof. Frédérique Penault-Llorca

Go Back

Pathologist

  • University of Clermont-Ferrand
  • location France

Frédérique PENAULT-LLORCA, MD, PhD, graduated as a medical specialist in pathology in 1993 and in oncology in 1995. Also, in 1995, she received a PhD from the Université d’Aix-Marseille II in cellular biology and microbiology, on the topic of HER2. Professor PENAULT-LLORCA is currently professor of Pathology at the University of Clermont-Ferrand, CEO of the Comprehensive Regional Cancer Institute Centre Jean PERRIN, deputy director of the research team INSERM 1240 IMoST, and head of the Molecular Biology Plateform at Centre Jean Perrin, Clermont-Ferrand, France, and Vice-President of UNICANCER GROUP. She chairs the Immuno- Oncology group at UNICANCER R&D. She is a member of several pathology and oncology societies (ESMO, ASCO, ECP, AIP, SFP. Her main areas of interest as a pathology being female cancers. Professor PENAULT-LLORCA has conducted various biomarkers-based research studies in breast, ovarian, colorectal, gastric, and lung cancer in relation to response to targeted therapies and immunotherapies. She also acts as a coordinating pathologist for various oncology trials. Professor PENAULT-LLORCA has written more than 440 peer-reviewed publications and several books on female cancers and biomarker testing methods and issues.

Prof. Frédérique Penault-Llorca has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Bayer and Roche. 

Programmes developed by Prof. Frédérique Penault-Llorca

video Video

Episode

1

of 4

episode
Oncology 
New Oral Endocrine Therapy Options for Patients with Advanced or Metastatic ER+ Breast Cancer – Episode 1

Overview of Clinical Data of SERDs & Their Place in Treatment Landscape

Experts
Dr Sara Tolaney, Dr Aditya Bardia, Prof. Frédérique Penault-Llorca
Endorsed by
SOLTI
GRASP
  • download Downloadable
    Resources
  • clock 18 MIN
  • calendar Jul 2023

Educational programme supported by an Independent Educational Grant from Menarini Stemline Oncology
video Video

Episode

2

of 4

episode
Oncology 
New Oral Endocrine Therapy Options for Patients with Advanced or Metastatic ER+ Breast Cancer – Episode 2

Optimisation of Treatment Selection & Sequencing Decisions in ER+/HER2- Advanced or Metastatic Breast Cancer

Experts
Dr Sara Tolaney, Dr Aditya Bardia, Prof. Frédérique Penault-Llorca
Endorsed by
SOLTI
GRASP
  • clock 14 MIN
  • calendar Jul 2023

Educational programme supported by an Independent Educational Grant from Menarini Stemline Oncology
video Video

Episode

3

of 4

episode
Oncology 
New Oral Endocrine Therapy Options for Patients with Advanced or Metastatic ER+ Breast Cancer – Episode 3

ESR1 Mutation: The Need for & Role of Testing in ER+/HER2- Advanced or Metastatic Breast Cancer

Experts
Dr Sara Tolaney, Dr Aditya Bardia, Prof. Frédérique Penault-Llorca
Endorsed by
SOLTI
GRASP
  • clock 20 MIN
  • calendar Jul 2023

Educational programme supported by an Independent Educational Grant from Menarini Stemline Oncology
video Video

Episode

4

of 4

episode
Oncology 
New Oral Endocrine Therapy Options for Patients with Advanced or Metastatic ER+ Breast Cancer – Episode 4

Panel Discussion and Summary

Experts
Dr Sara Tolaney, Dr Aditya Bardia, Prof. Frédérique Penault-Llorca
Endorsed by
SOLTI
GRASP
  • clock 19 MIN
  • calendar Jul 2023

Educational programme supported by an Independent Educational Grant from Menarini Stemline Oncology
other Other
TRK fusion-positive cancer: new ESMO OncologyPRO learning resource

Experts
Prof. Ezra Cohen, Prof. Frédérique Penault-Llorca, Prof. Silvia Stacchiotti, Prof. Andrea Sartore-Bianchi, Prof. Fernando López-Ríos, Prof. Christian Rolfo
  • clock 30 MIN
  • calendar Aug 2022

video Video
Oncology 
Using immunohistochemistry to detect TRK fusion-positive cancer

Experts
Prof. Frédérique Penault-Llorca
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar May 2022